SYDNEY and KUALA LUMPUR, Sep 7 2021 (IPS) – Vaccine costs have pushed many developing countries to the end of the COVID-19 vaccination queue, with most low-income ones not even lining up. Worse, less vaccinated poor nations cannot afford fiscal efforts to provide relief or stimulate recovery, let alone achieve Agenda 2030.
Anis Chowdhury
Excluding by appropriating
Developing countries now account for . By early September, estimated actual COVID-19 deaths worldwide at 15.2 million, rather than the official 4.6 million.
In with the highest fatality rates, less than a tenth of their populations were fully vaccinated as of 10 August. In the other four, no more than a third were fully vaccinated.
Now, as rich nations buy up more vaccines for third shots, vaccination inequities are becoming starker. , they penalise poorer countries already doubly deprived. Rich countries will likely have about !
have been administered worldwide, with 81% in only ten high and upper middle-income countries. Meanwhile, the poorest countries have only received 0.4%.
In January, the World Health Organization (WHO) Director-General (DG) , “I need to be blunt: the world is on the brink of a catastrophic moral failure – and the price of this failure will be paid with lives and livelihoods in the world’s poorest countries”.
Profits booster
In early July, Pfizer and BioNTech plans to get emergency authorisation for booster vaccine doses. Pfizer then met with US officials to press their case, while Moderna this month.
Jomo Kwame Sundaram
Following the third shot on 30 July, nearly have been administered in the US since 12 August despite earlier official . US President Joe Biden for a further 100 million booster shots on 20 September.
began administering boosters to people over 65 from September. The offering a third dose from late September. followed suit.
Now, supply will decline further as Pfizer and Moderna sell booster doses. have been approved to manufacture boosters in France and Germany.
Meanwhile, booster production in Massachusetts and New Hampshire. Almost Pfizer and Moderna doses to be produced this year have already been purchased by the US and Europe.
The WHO DG lambasted this “” at the World Health Assembly in May. The WHO has booster provision, arguing that the most vulnerable people worldwide should be vaccinated first.
Pfizer and Moderna of their booster prices. An has estimated: “Sold at present prices, this would represent roughly a 50% increase in revenue over the longer run”.
its 2021 vaccine sales forecast for its first two doses to US$19.2 billion in May. So, booster sales should add about US$10 billion. Meanwhile, its own forecast by more than 70% to US$26 billion, with booster sales bringing US$13 billion more.
Related IPS Articles
Profits over science
Rich countries’ practices actually go against most scientific advice. The case for boosters is not scientifically established. Most that boosters are the best way to deal with new threats. Citing , scientists have opposed boosters in , including .
On 6 August, the noted not enough evidence to recommend COVID-19 vaccine boosters. A report this month affirmed, “there is no urgent need” for booster shots except for those in frail health.
The WHO noted on 18 August that for booster shots. Scientists described official decisions approving third booster shots as . When US authorities approved boosters, two top vaccine officials .
on Pfizer’s two-dose vaccine suggests it provides long-term immunity , contrary to the company’s latest claims. Also using mRNA technology, Moderna’s vaccine should have .
As COVID-19 vaccines are still new, such expectations remain subject to confirmation. As with most vaccines, ‘’ triggers antibody protection when someone vaccinated is infected, even after natural response levels have waned.
Perhaps most worryingly, as big pharmaceutical companies transform their business strategies to generate more profits from boosters, their incentives change. They have less reason to develop vaccines fully immunizing against the COVID-19 virus, or even to ensure that everyone is vaccinated.
Apartheid booster
Supplying boosters reduces vaccines available to others. Supplies to poorer countries have already been greatly reduced by rich countries securing many times more than what their populations need.
Some COVAX, purportedly designed for equitable distribution to poorer countries. COVAX aimed to deliver a billion vaccine doses in 2021, but had only delivered 217 million by August, according to .
Meanwhile, the request to the World Trade Organization to temporarily suspend COVID-19 related intellectual property rights. This waiver would enable developing countries to affordably produce tests, vaccines, treatments, equipment and other such needs.
Earlier, Big Pharma leaders rejected as “” WHO’s initiative to share technologies and research knowledge to accelerate affordable production of and access to such technologies.
Vaccine equity necessary
There is also a practical reason to seek vaccine equity. We are all safer when everyone is vaccinated. , endangering everyone.
Rich countries protecting their own citizens will not prevent new mutants from emerging. New infections risk triggering a resurgence, or worse, with new, more dangerous mutations.
The , first reported in India in late 2020, surged in March as few there had been vaccinated. Ironically, the Serum Institute of India has the world’s largest vaccine production capacity by far, but largely underutilised for COVID-19 vaccines.
The highly infectious variants could derail economic recovery, cutting global output by US$4.5 trillion by 2025. But the Economist Intelligence Unit the world economy could lose US$2.3 trillion in 2021 alone due to delayed vaccinations, with developing nations losing most.
For the , “Vaccine inequity is the world’s biggest obstacle to ending this pandemic and recovering from COVID-19 .Economically, epidemiologically and morally, it is in all countries’ best interest to use the latest available data to make lifesaving vaccines available to all”.
